Related Experiment Video

Updated: Apr 11, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

6.9K

Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled

Seon Ha Baek1, Se Hyun Kim2, Jin Won Kim3

  • 1Division of Nephrology, Department of Internal Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam, Gyeonggi-do, 463-707, South Korea. haya2001@hanmail.net.

Trials
|May 30, 2015
PubMed
Abstract

Insights

This study investigates if gemigliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, can prevent acute kidney injury (AKI) caused by cisplatin chemotherapy in humans. The trial aims to determine the drug

Area of Science:

  • Nephrology
  • Oncology
  • Pharmacology

Background:

  • Cisplatin chemotherapy can cause significant kidney damage, known as acute kidney injury (AKI), limiting its use.
  • Previous research in mice suggested that dipeptidyl peptidase-4 (DPP4) inhibitors may protect the kidneys from cisplatin-induced damage.
  • No effective clinical interventions currently exist to prevent cisplatin-induced nephrotoxicity.

Purpose of the Study:

  • To evaluate the efficacy of a DPP4 inhibitor, gemigliptin, in preventing cisplatin-induced AKI in human patients.
  • To assess the renoprotective effects of gemigliptin in the context of cancer chemotherapy.

Main Methods:

  • A single-center, prospective, randomized, double-blind, placebo-controlled trial involving 182 participants.
  • Participants received either gemigliptin or a placebo for 8 days, starting one day before cisplatin treatment.
  • Primary outcome: incidence of AKI at 7 days post-treatment. Secondary outcomes: changes in serum creatinine and estimated glomerular filtration rate.

Main Results:

  • The study is the first clinical trial to examine the effect of a DPP4 inhibitor on cisplatin-induced AKI.
  • Results regarding the incidence of AKI and changes in renal function markers are pending analysis.

Conclusions:

  • This trial represents a novel investigation into a potential therapeutic strategy for mitigating chemotherapy-induced kidney damage.
  • Findings will inform future clinical practice regarding the use of DPP4 inhibitors in patients undergoing cisplatin treatment.

More Related Videos

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats06:38

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats

Published on: March 11, 2016

12.7K
Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research03:13

Technical Refinement of a Bilateral Renal Ischemia-Reperfusion Mouse Model for Acute Kidney Injury Research

Published on: November 3, 2023

3.2K

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
515
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
1.3K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
2.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
327
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
498